ArticleZeitschrift fur Rheumatologie2013
[ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area].
Article in Zeitschrift fur Rheumatologie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].Zeitschrift fur Rheumatologie · 2014Guideline
- [Evidence-based recommendations on diagnostics and therapy of axial spondyloarthritis : S3 guidelines of the German Society of Rheumatology (DGRh) in cooperation with the Association of the Scientific Medical Societies in Germany (AWMF)].Zeitschrift fur Rheumatologie · 2017Review
- [What is ascertained in the therapy of axial spondyloarthritis?].Der Internist · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ASAS recommendations on the use of tumor necrosis factor (TNF) inhibitors for patients with axial spondyloarthritis were amended in 2010. Essential new aspects have been included in the update. The diagnosis is extended from patients with ankylosing spondlitis (AS) to all patient groups of axial spondyloarthritis. Pretreatment with at least two non-steroidal anti-rheumatic drugs (NSARD) for 4 weeks is recommended. The success of therapy with TNF inhibitors is to be compiled after at least 12 weeks.This article presents the results of the evaluation of the German translation of these recommendations. A total of 25 experts from Germany, Austria and Switzerland have scored the translation on a scale between 0 (no agreement) and 10 (full agreement) with respect to the recommendation grade. The agreement on the recommendations between the experts was very high (8.98 ± 1.25).
Indexed as
Identifiers
23338704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.